BiomedicalPublications

Antibody Therapeutics

Oxford University Press·United States·ISSN 2516-4236

Open accessIn DOAJFee waivers availableMedicine

Antibody Therapeutics is published by Oxford University Press as an open access journal (ISSN 2516-4236). The list article processing charge is $2,822. Typical time to publication is 8 wks. Its OpenAlex h-index is 33. Primary field: Medicine. It is listed in the Directory of Open Access Journals. Fee waivers are stated as available. Figures on this page are sourced from OpenAlex and DOAJ and should be confirmed on the journal’s own site before submission.

Cost to publish

$2,822

Open-access article processing charge, list price.

Checked · Journal fee page

Time to publication

8 wks

Fast for a peer-reviewed journal — check what review depth that implies.

h-index

33

OpenAlex citation statistic. Not a Journal Impact Factor.

2-year mean citedness

3.1

Average citations to articles from the previous two years.

What it costs to publish here

Publishing an open-access article in Antibody Therapeutics is listed at $2,822. The journal reports that fee waivers are available — worth pursuing if you are funding this yourself or working from a lower-income country.

The journal's own fee page →

What this journal has charged over time

List price for an open-access article in Antibody Therapeutics, as recorded by OpenAlex for each year. The fee has risen 8% since 2021, from $2,625 to $2,822.

$0$1.5k$3k2021: $2,62520212022: $2,62520222023: $2,63520232024: $2,96320242025: $2,8222025

Publishers change list prices without notice and often apply discounts, institutional agreements or waivers. Treat this as the trend, and confirm the current figure with the journal.

Peer review and licensing

Review modelAnonymous peer review (policy)
LicenceCC BY, CC BY-NC
Author keeps copyrightNo
Plagiarism screeningYes
Editorial boardPublished →
LanguagesEN

Verification checks

8 of 8 confirmed

These are facts we could verify in public records, not a verdict. A journal missing a check is not necessarily disreputable — many long-established subscription journals sit outside the open-access registries entirely. Use them as questions to ask, and confirm anything that matters directly with the journal before you submit.

  • Listed in the Directory of Open Access JournalsDOAJ applies a documented set of inclusion criteria.
  • Included in OpenAlex's curated core setOpenAlex flags well-established venues that appear across major indexes.
  • Peer review model publicly declaredAnonymous peer review
  • Publication charges stated up frontA journal that will not tell you the fee before submission is worth a second look.
  • Screens submissions for plagiarismReported to DOAJ by the journal.
  • Participates in a digital preservation schemeArchiving means the record survives if the publisher does not.
  • Assigns persistent identifiers (DOIs)Standard practice; its absence is unusual.
  • Still actively publishingMost recent indexed article: 2026.

Scope

The subjects Antibody Therapeutics publishes most, derived from the topics assigned to its indexed articles.

Monoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy researchProtein purification and stabilityHER2/EGFR in Cancer ResearchSARS-CoV-2 and COVID-19 ResearchGlycosylation and Glycoproteins ResearchImmunotherapy and Immune ResponsesViral Infectious Diseases and Gene Expression in Insectsvaccines and immunoinformatics approachesTransgenic Plants and Applications

Publication record

Indexed articles290
Total citations3,718
i10-index84
Most recent indexed article2026
Open access since2018
All ISSNs2516-4236

Counts reflect what OpenAlex has indexed and will differ from the publisher's own figures. We do not show a founding year: OpenAlex's first-publication dates are distorted by mis-dated records — it puts PLoS ONE in 1806 — and we would rather omit a number than print one we cannot stand behind.